Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24 Febbraio 2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22 Febbraio 2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27 Gennaio 2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17 Gennaio 2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08 Gennaio 2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
05 Dicembre 2022
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28 Novembre 2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21 Novembre 2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18 Ottobre 2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22 Settembre 2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05 Settembre 2022
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31 Agosto 2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27 Luglio 2022
Chiesi tracks actions taken for a healthier, more sustainable future
14 Luglio 2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02 Maggio 2022
Solidarity actions to support the people affected by the war
08 Aprile 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
07 Aprile 2022
Chiesi Group continues to grow
31 Marzo 2022
Koura opens world’s first HFA 152a medical propellant production facility
30 Marzo 2022
Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
19 Gennaio 2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16 Dicembre 2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14 Dicembre 2021
Chiesi Group Headquarters takes centre stage in the monograph “SPAZIO LAVORO ARCHITETTURA” (SPACE WORK ARCHITECTURE) Electaarchitettura editions
13 Dicembre 2021
Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
30 Novembre 2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18 Ottobre 2021
Chiesi receives positive ESG rating from independent rating agency Cerved
23 Settembre 2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07 Settembre 2021
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
06 Settembre 2021
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
23 Giugno 2021
Chiesi Group calls for #ActionOverWords in the fight against climate change
10 Maggio 2021
New organisational order for the Chiesi Foundation
03 Maggio 2021
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
21 Aprile 2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
22 Marzo 2021
Chiesi Group: performance is up in 2020
09 Marzo 2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
26 Febbraio 2021
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
01 Febbraio 2021
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
27 Gennaio 2021
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
14 Gennaio 2021
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
30 Novembre 2020
Chiesi Group receives Diversity Leaders Award 2021
19 Novembre 2020
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
17 Novembre 2020
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
15 Ottobre 2020
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
24 Settembre 2020
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
18 Settembre 2020
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
17 Settembre 2020
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
16 Luglio 2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10 Luglio 2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
02 Luglio 2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
29 Giugno 2020
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
27 Marzo 2020
Chiesi Group Announces Establishment of New Global Rare Diseases Division
06 Febbraio 2020
Chiesi Group confirmed Top Employer 2020 in Italy and Europe
30 Gennaio 2020
Chiesi Group sponsors Parma Capital of Culture 2020
10 Gennaio 2020
Chiesi Group joins the Cooperative Compliance Programme run by the Italian Revenue Agency
18 Dicembre 2019
Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
04 Dicembre 2019
Chiesi Group receives Diversity Leaders Award 2020
20 Novembre 2019
SINGLE-INHALER EXTRAFINE TRIPLE THERAPY OF INHALED CORTICOSTEROID PLUS LONG-ACTING Β2-AGONIST PLUS LONG-ACTING MUSCARINIC ANTAGONIST THERAPY IMPROVES LUNG FUNCTION AND REDUCES ASTHMA EXACERBATIONS1
01 Ottobre 2019
We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035
25 Settembre 2019
Chiesi Group confirms positive trend to date for 2019
09 Luglio 2019
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
06 Giugno 2019
Paolo Chiesi appointed Honorary Doctor at Karolinska Institutet
10 Maggio 2019
Chiesi Group receives the EURORDIS Black Pearl Award for innovation in the field of Rare Disease.
13 Febbraio 2019
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
04 Febbraio 2019
COPD, a disease still underestimated by Europeans: absence of perceived risk, according to Eurisko survey.
21 Novembre 2018
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
03 Settembre 2018
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa)
24 Luglio 2018
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
12 Giugno 2018
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
04 Aprile 2018
Chiesi hosts groundbreaking ceremony for the Group’s future Headquarters
22 Marzo 2018
New study published in The Lancet shows Trimbow® (beclometasone/formoterol/glycopyrronium) superiority over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
13 Febbraio 2018
Chiesi Group confirmed Top Employer 2018 in Italy and Europe
05 Febbraio 2018
Chiesi Group receives positive opinion from CHMP for Lamzede® (velmanase alfa), the first therapy for Alpha-Mannosidosis
29 Gennaio 2018
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
23 Gennaio 2018
Chiesi is the first Italian pharmaceutical Company for investments in Research and Development
20 Dicembre 2017
TRIBUTE study shows superiority of Chiesi's Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
07 Settembre 2017
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
24 Luglio 2017
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
22 Maggio 2017
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
20 Aprile 2017
Glybera▼ (alipogene tiparvovec) in Europe
20 Aprile 2017
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
21 Novembre 2016
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
08 Novembre 2016
Chiesi Farmaceutici is the first company to submit a marketing authorisation application to the European Medicine Agency for a Triple Combination for the treatment of COPD
29 Settembre 2016
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study
02 Settembre 2016
Patients with COPD benefit from the Chiesi extrafine fixed triple combination ICS/LABA/LAMA: highly effective and easy to use.
27 Maggio 2016
An extrafine ICS/LABA combination decreases COPD exacerbations more than
17 Maggio 2016
Chiesi To Acquire 3 Hospital Products
10 Maggio 2016
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
31 Marzo 2016
Europe approves Holoclar®, the first stem cell—based medicinal product
20 Febbraio 2015
PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY
